Overview


Cervical intraepithelial neoplasia (CIN) is a condition in which abnormal cells proliferate inside the cervix. It can be caused by some types of the human papillomavirus (HPV), as well as other environmental factors, and it can occasionally progress to cervical cancer precursors. Cervical intraepithelial neoplasia is more prevalent than cervical cancer. The cervix is the lower portion of the uterus that enters the vaginal canal. The cervix dilates during childbirth to allow the foetus to pass through. In cervical intraepithelial neoplasia, the abnormal cells aren't cancerous. If not watched or treated in certain circumstances that necessitate therapy, it might develop into precancers or cancer. Cervical dysplasia is another name for this disorder.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Cervical Intraepithelial Neoplasia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Cervical Intraepithelial Neoplasia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Boehringer Ingelheim International GmbH.
• AstraZeneca
• Johnson
Johnson Private Limited
• MerckCo., Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Biocon
• Amgen Inc.
• Eli Lilly and Company
• Allergan
• Hetero
• Abbott
• QIAGEN
• Danaher
(Note: The list of the major players will be updated with the latest market scenario and trends)
By Disease Type
• Cervical Intraepithelial Neoplasia 1
• Cervical Intraepithelial Neoplasia 2
• Cervical Intraepithelial Neoplasia 3
By Treatment
• Surgery
• Hysterectomy
• Cone biopsy
• Loop electrosurgical excision procedure (LEEP)
• Laser therapy
• Cryosurgery
• Medication
• Avastin
• Bevacizumb
• Blemocin
• Blenoxane
• Others
By Indication
• Pre-malignant Lesions
• Early Invasive Stage
• Advanced Invasive Stage
By Dosage Form
• Solution
• Powder
• Injection
• Cream
• Others
By Route of Administration
• Intravenous
• Topical
• Others
By End-Users
• Hospitals
• Specialty Clinics
• Homecare
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others
By Region
North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
• To provide with an exhaustive analysis on the Cervical Intraepithelial Neoplasia Drugs Market By Disease Type, By Treatment, By Indication, By Dosage Form, By Route of Administration, By End-Users, By End Users and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Cervical Intraepithelial Neoplasia Drugs Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Cervical Intraepithelial Neoplasia Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Cervical Intraepithelial Neoplasia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Cervical Intraepithelial Neoplasia Drugs Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Cervical Intraepithelial Neoplasia 1
        2. Cervical Intraepithelial Neoplasia 2
        3. Cervical Intraepithelial Neoplasia 3
  • 8.   Cervical Intraepithelial Neoplasia Drugs Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Surgery
        2. Hysterectomy
        3. Cone biopsy
        4. Loop electrosurgical excision procedure (LEEP)
        5. Laser therapy
        6. Cryosurgery
        7. Medication
        8. Avastin
        9. Bevacizumb
        10. Blemocin
        11. Blenoxane
        12. Others
  • 9.   Cervical Intraepithelial Neoplasia Drugs Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Pre-malignant Lesions
        2. Early Invasive Stage
        3. Advanced Invasive Stage
  • 10.   Cervical Intraepithelial Neoplasia Drugs Market, By Dosage Form Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Solution
        2. Powder
        3. Injection
        4. Cream
        5. Others
  • 11.   Cervical Intraepithelial Neoplasia Drugs Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Intravenous
        1. Topical
        1. Others
  • 12.   Cervical Intraepithelial Neoplasia Drugs Market, By End-Users Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others
  • 13.   Cervical Intraepithelial Neoplasia Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others
  • 14.   North America Cervical Intraepithelial Neoplasia Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 15.   Latin America Cervical Intraepithelial Neoplasia Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 16.   Europe Cervical Intraepithelial Neoplasia Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 17.   Asia Pacific Cervical Intraepithelial Neoplasia Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 18.   Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 19.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 20.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    • 1. Pfizer Inc.
               1.1. Company Overview
               1.2. Product Portfolio
               1.3. SWOT Analysis
               1.4. Financial Overview
               1.5. Strategic Overview
         2. GlaxoSmithKline plc
               2.1. Company Overview
               2.2. Product Portfolio
               2.3. SWOT Analysis
               2.4. Financial Overview
               2.5. Strategic Overview
         3. Novartis AG
               3.1. Company Overview
               3.2. Product Portfolio
               3.3. SWOT Analysis
               3.4. Financial Overview
               3.5. Strategic Overview
         4. Mylan N.V.
               4.1. Company Overview
               4.2. Product Portfolio
               4.3. SWOT Analysis
               4.4. Financial Overview
               4.5. Strategic Overview
         5. Teva Pharmaceutical Industries Ltd.
               5.1. Company Overview
               5.2. Product Portfolio
               5.3. SWOT Analysis
               5.4. Financial Overview
               5.5. Strategic Overview          
         6. Sanofi
               6.1. Company Overview
               6.2. Product Portfolio
               6.3. SWOT Analysis
               6.4. Financial Overview
               6.5. Strategic Overview      
         7. Boehringer Ingelheim International GmbH.
               7.1. Company Overview
               7.2. Product Portfolio
               7.3. SWOT Analysis
               7.4. Financial Overview
               7.5. Strategic Overview
         8. AstraZeneca
               8.1. Company Overview
               8.2. Product Portfolio
               8.3. SWOT Analysis
               8.4. Financial Overview
               8.5. Strategic Overview
         9. Johnson & Johnson Private Limited
               9.1. Company Overview
               9.2. Product Portfolio
               9.3. SWOT Analysis
               9.4. Financial Overview
               9.5. Strategic Overview
         10. Merck & Co., Inc.
               10.1. Company Overview
               10.2. Product Portfolio
               10.3. SWOT Analysis
               10.4. Financial Overview
               10.5. Strategic Overview
          11. F. Hoffmann-La Roche Ltd.
                11.1. Company Overview
                11.2. Product Portfolio
                11.3. SWOT Analysis
                11.4. Financial Overview
                11.5. Strategic Overview
          12. Bristol-Myers Squibb Company
                12.1. Company Overview
                12.2. Product Portfolio
                12.3. SWOT Analysis
                12.4. Financial Overview
                12.5. Strategic Overview
          13. Biocon
                13.1. Company Overview
                13.2. Product Portfolio
                13.3. SWOT Analysis
                13.4. Financial Overview
                13.5. Strategic Overview
          14. Evado Pty. Ltd.
                14.1. Company Overview
                14.2. Product Portfolio
                14.3. SWOT Analysis
                14.4. Financial Overview
                14.5. Strategic Overview
          15. Amgen Inc.
                15.1. Company Overview
                15.2. Product Portfolio
                15.3. SWOT Analysis
                15.4. Financial Overview
                15.5. Strategic Overview          
          16. Eli Lilly and Company
                16.1. Company Overview
                16.2. Product Portfolio
                16.3. SWOT Analysis
                16.4. Financial Overview
                16.5. Strategic Overview      
          17. Allergan
                17.1. Company Overview
                17.2. Product Portfolio
                17.3. SWOT Analysis
                17.4. Financial Overview
                17.5. Strategic Overview
          18. Hetero
                18.1. Company Overview
                18.2. Product Portfolio
                18.3. SWOT Analysis
                18.4. Financial Overview
                18.5. Strategic Overview
          19. Abbott
                19.1. Company Overview
                19.2. Product Portfolio
                19.3. SWOT Analysis
                19.4. Financial Overview
                19.5. Strategic Overview
            20. QIAGEN
                20.1. Company Overview
                20.2. Product Portfolio
                20.3. SWOT Analysis
                20.4. Financial Overview
                20.5. Strategic Overview
          21. Danaher
                21.1. Company Overview
                21.2. Product Portfolio
                21.3. SWOT Analysis
                21.4. Financial Overview
                21.5. Strategic Overview

  • 21.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 22.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients